Open an account

Evommune

EVMN · NYSE

$5.38+$0.11 (+2.09%)TodayMarket closed ·
Prev close $5.27

About EVMN

The company is headquartered in Palo Alto, California and currently employs 48 full-time employees. The company went IPO on 2025-11-06.

Employees
48
Headquarters
Palo Alto, California
Listed
Nov 6, 2025
Sector
Health Care
Industry
Biotechnology
Website
evommune.com

EVMN key statistics

Market cap
195.25M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
893.52K
Volume
382.46K
Open price
$5.33
High today
$5.70
Low today
$5.33
52 Week high
$33.20
52 Week low
$5.09

Evommune (EVMN) at a glance

As of Oct 20, 2026, Evommune (EVMN) shares are priced at $5.38, giving the company a market cap of 195.25M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.33 and $5.70. The current price is 0.9% above the day's low and 5.6% below its high.

Volume so far is 382.46K shares, below the average of 893.52K shares a day.

Over the past year Evommune has ranged from $5.09 to $33.20, and now sits 1% of the way up that range.

Evommune met or beat analyst EPS estimates in 1 of the last 3 quarters. In Q2 FY26 it reported -$0.89 per share against an estimate of -$0.6814.

The average analyst price target is $24.48, 355.0% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 12 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 11 analystsAvg $24.48
Low
$18.18
Now
$5.38
High
$31.50

EVMN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 3 quarters, by 15.6% on average.

  1. Q4 FY25: reported -$1.43 per share against an estimate of -$0.901
  2. Q1 FY26: reported -$0.64 per share against an estimate of -$0.7582
  3. Q2 FY26: reported -$0.89 per share against an estimate of -$0.6814

EVMN news

  • Press releaseBusiness Wire

    Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

  • Press releaseBusiness Wire

    Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Vandana Singh

    Evommune Halts Atopic Dermatitis Program Following Trial Failure

  • Press releaseBusiness Wire

    Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

  • Press releaseBusiness Wire

    Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

  • Press releaseBusiness Wire

    Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

  • Press releasePRNewswire

    Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Similar companies

Companies in the same industry as Evommune

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.